Press coverage about Icon (NASDAQ:ICLR) has been trending somewhat positive on Friday, according to Accern Sentiment. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Icon earned a coverage optimism score of 0.04 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 44.5744487582873 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Several equities analysts recently commented on the stock. Zacks Investment Research downgraded shares of Icon from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Credit Suisse Group reaffirmed an “outperform” rating and set a $120.00 price objective (up previously from $105.00) on shares of Icon in a research report on Monday, October 16th. Jefferies Group reaffirmed a “buy” rating and set a $122.00 price objective on shares of Icon in a research report on Tuesday, September 12th. Bank of America initiated coverage on shares of Icon in a research report on Monday, September 11th. They set a “buy” rating and a $128.00 price objective for the company. Finally, ValuEngine raised shares of Icon from a “hold” rating to a “buy” rating in a report on Friday, September 1st. Four research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. Icon currently has an average rating of “Buy” and an average price target of $121.00.
Shares of Icon (NASDAQ ICLR) traded up $0.92 during midday trading on Friday, reaching $113.59. 203,700 shares of the company were exchanged, compared to its average volume of 357,566. The company has a market cap of $6,203.11, a price-to-earnings ratio of 22.01, a PEG ratio of 1.77 and a beta of 0.56. Icon has a 1-year low of $73.93 and a 1-year high of $124.48. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31.
Icon (NASDAQ:ICLR) last released its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, beating analysts’ consensus estimates of $1.32 by $0.03. The business had revenue of $440.30 million during the quarter, compared to the consensus estimate of $438.09 million. Icon had a net margin of 16.37% and a return on equity of 28.42%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.19 EPS. analysts predict that Icon will post 5.37 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Icon (ICLR) Earning Somewhat Favorable News Coverage, Study Finds” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thelincolnianonline.com/2017/12/22/icon-iclr-earning-somewhat-favorable-news-coverage-study-finds.html.
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
Receive News & Ratings for Icon Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Icon and related companies with MarketBeat.com’s FREE daily email newsletter.